Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer

被引：0
作者：
Tatsuya Miyazaki
Makoto Sohda
Naritaka Tanaka
Shigemasa Suzuki
Keisuke Ieta
Makoto Sakai
Akihiko Sano
Takehiko Yokobori
Takanori Inose
Masanobu Nakajima
Minoru Fukuchi
Hitoshi Ojima
Hiroyuki Kato
Hiroyuki Kuwano
机构：
[1] Gunma University Graduate School,Department of General Surgical Science (Surgery 1)
[2] Dokkyo Medical University,First Department of Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 71卷
关键词：
Docetaxel; Nedaplatin; 5-Fluorouracil; Chemotherapy; Esophageal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
More effective protocols are needed for unresectable and recurrent esophageal cancer. Therefore, we conducted a phase I trial to establish the recommended dose of docetaxel, nedaplatin, and 5-fluorouracil (DNF) as combination chemotherapy. Fourteen patients with esophageal cancer were enrolled and received DNF combination therapy at different dose levels according to the treatment and examination plan. Dose-limiting toxicities (DLTs) included febrile neutropenia. DLTs occurred in 3/5 patients at level 4. The recommended doses (level 3) of DNF were 60 mg/m2 (day 1), 70 mg/m2 (day 1), and 700 mg/m2 (days 1–5), respectively, given at 3-week intervals. In conclusion, DNF combined chemotherapy for advanced esophageal cancer was associated with relatively minor adverse events and was safely administered at the recommended dose. A phase II study is now underway.
引用
收藏
页码：853 / 857
页数：4
相关论文
共 163 条
  • [1] Ajani JA(1992)Prolonged chemotherapy for localised squamous carcinoma of the oesophagus Eur J Cancer 28A 880-884
  • [2] Ryan B(1988)Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus Ann Thorac Surg 45 357-363
  • [3] Rich TA(1992)Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial Jpn J Clin Oncol 22 172-176
  • [4] McMurtrey M(2011)Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer Anticancer Res 31 633-638
  • [5] Roth JA(2003)Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas Anticancer Res 23 3493-3498
  • [6] DeCaro L(2010)A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma Chin J Cancer 29 321-324
  • [7] Levin B(2004)A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer Ann Oncol 15 955-959
  • [8] Mountain C(2002)Docetaxel for gastric and esophageal carcinomas Oncology (Williston Park) 16 89-96
  • [9] Hilgenberg AD(2011)Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial Lancet Oncol 12 153-159
  • [10] Carey RW(2011)Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer Anticancer Res 31 3535-3541
12345678910